U.S. Markets closed

BioDelivery Sciences International, Inc. (BDSI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.90+0.10 (+3.57%)
At close: 4:00PM EDT

2.90 0.00 (0.00%)
After hours: 4:00PM EDT

People also watch
BCRXFOLDSPPIVNDAACHN
Full screen
Previous Close2.80
Open2.80
Bid2.80 x 400
Ask2.90 x 1300
Day's Range2.65 - 2.90
52 Week Range1.50 - 3.10
Volume611,913
Avg. Volume663,289
Market Cap160.45M
Beta1.27
PE Ratio (TTM)-2,900.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals5 days ago

    Raleigh's BDSI expands international distribution of Belbuca

    Raleigh’s BioDelivery Sciences International (BDSI) is continuing on its Belbuca run since reacquiring the pain management product from Endo Pharmaceuticals earlier this year. BDSI announced Friday that Belbuca has received Health Canada approval and that it expects to launch the product in Canada early next year with a commercial partner. “BDSI has not yet announced a partner for Canada, though we have been in discussions with potential partners.

  • Capital Cube6 days ago

    ETFs with exposure to BioDelivery Sciences International, Inc. : June 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioDelivery Sciences International, Inc. Here are 5 ETFs with the largest exposure to BDSI-US. Comparing the performance and risk of BioDelivery Sciences International, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • BioDelivery Inks New Contract with CVS/Caremark, Shares Up
    Zacks6 days ago

    BioDelivery Inks New Contract with CVS/Caremark, Shares Up

    BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.